Nanomedicine for the prevention, treatment and imaging of atherosclerosis

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue SUPPL. 1, 2012, Pages

  Psarros, Costas ^a   Lee, Regent ^a   Margaritis, Marios ^a   Antoniades, Charalambos ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atherosclerosis; Drug delivery systems; Inflammation; Liposomes; Nanotechnology

Indexed keywords

AGING POPULATION; ARTERIAL WALL; ATHEROSCLEROSIS; ATHEROSCLEROTIC LESIONS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CEREBRAL ISCHEMIA; CHRONIC INFLAMMATORY; DEVELOPED COUNTRIES; DRUG DELIVERY SYSTEM; FOAM CELLS; INFLAMMATION; LOW DENSITY LIPOPROTEINS; POTENTIAL APPLICATIONS; THERAPEUTIC STRATEGY;

DRUG DELIVERY; LIPOSOMES; MEDICAL NANOTECHNOLOGY; NANOTECHNOLOGY; PATHOLOGY;

DISEASES;

ADENOSINE DIPHOSPHATE; C REACTIVE PROTEIN; CALCIUM ION; CD31 ANTIGEN; DENDRIMER; DIPEPTIDYL CARBOXYPEPTIDASE; FULLERENE; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOSOME; LOW DENSITY LIPOPROTEIN; MACROGOL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; POLYAMIDOAMINE; PUTRESCINE; QUANTUM DOT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SERUM AMYLOID A; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VIMENTIN;

ARTERY WALL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ECHOGRAPHY; ENDOCYTOSIS; FOAM CELL; HALF LIFE TIME; HEART MUSCLE ISCHEMIA; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MOLECULAR INTERACTION; NANODEVICE; NANOMEDICINE; NANOTOXICOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; RNA INTERFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTE AGGREGATION; THROMBOGENICITY; UPREGULATION;

ANIMALS; ATHEROSCLEROSIS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84865576295     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.05.006     Document Type: Review

References (91)

1. Mackay J., Mensah G. Atlas of heart disease and stroke 2004, World Health Organization (WHO), Geneva Press.
2. Antoniades C., Antonopoulos A.S., Bendall J.K., Channon K.M. Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr Pharm Des 2009, 15:329-342.
3. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84:1381-1478.
4. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
5. Goldberg M., Langer R., Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 2007, 18:241-268.
6. Antoniades C., Psarros C., Tousoulis D., Bakogiannis C., Shirodaria C., Stefanadis C. Nanoparticles a promising therapeutic approach in atherosclerosis. Cancer Drug Deliv 2010, 7:303-311.
7. Jain R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 2001, 74:7-25.
8. Qiu L.Y., Bae Y.H. Polymer architecture drug delivery. Pharm Res 2006, 23:1-30.
9. Schwendener R.A. Liposomes in biology and medicine. Adv Exp Med Biol 2007, 620:117-128.
10. Christian D.A., Cai S., Bowen D.M., Kim Y., Pajerowski J.D., Discher D.E. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur J Pharm Biopharm 2009, 71:463-474.
11. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
12. Shin J., Shum P., Thompson D.H. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J Control Release 2003, 91:187-200.
13. Zalipsky S., Qazen M., Walker J.A., Mullah N., Quinn Y.P., Huang S.K. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 1999, 10:703-707.
14. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005, 353:1711-1723.
15. Pepine C.J., Hirshfeld J.W., Macdonald R.G., et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation 1990, 81:1753-1761.
16. Stone G.W., Rutherford B.D., McConahay D.R., et al. A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Catheter Cardiovasc Diagn 1989, 18:227-231.
17. Joner M., Morimoto K., Kasukawa H., et al. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol 2008, 28:1960-1966.
18. Woollard K.J., Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010, 7:77-86.
19. Chono S., Tauchi Y., Deguchi Y., Morimoto K. Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice. J Drug Target 2005, 13:267-276.
20. Chono S., Tauchi Y., Morimoto K. Pharmacokinetic analysis of the uptake of liposomes by macrophages and foam cells in vitro and their distribution to atherosclerotic lesions in mice. Drug Metab Pharmacokinet 2006, 21:37-44.
21. Homem de Bittencourt P.I., Lagranha D.J., Maslinkiewicz A., et al. LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis 2007, 193:245-258.
22. Tam S.P., Ancsin J.B., Tan R., Kisilevsky R. Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-/- mice. J Lipid Res 2005, 46:2091-2101.
23. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2:347-360.
24. Brocchini S., Duncan R. Encyclopaedia of controlled drug delivery 1999, Wiley, New York, NY.
25. Peng T., Cheng Y.L. Polymer 2001, 42:2091.
26. Duncan R., Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin Pharmacokinet 1994, 27:290-306.
27. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996, 13:1838-1845.
28. Photos P.J., Bacakova L., Discher B., Bates F.S., Discher D.E. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003, 90:323-334.
29. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42:463-478.
30. Mulder W.J., Strijkers G.J., Briley-Saboe K.C., et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007, 58:1164-1170.
31. Briley-Saebo K.C., Shaw P.X., Mulder W.J., et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008, 117:3206-3215.
32. Winter P.M., Neubauer A.M., Caruthers S.D., et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2103-2109.
33. Winter P.M., Caruthers S.D., Kassner A., et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003, 63:5838-5843.
34. Antoniades C., Psarros C., Tousoulis D., Bakogiannis C., Shirodaria C., Stefanadis C. Nanoparticles: a promising therapeutic approach in atherosclerosis. Cancer Drug Deliv 2010, 7:303-311.
35. Chnari E., Lari H.B., Tian L., Uhrich K.E., Moghe P.V. Nanoscale anionic macromolecules for selective retention of low-density lipoproteins. Biomaterials 2005, 26:3749-3758.
36. Nagle T., Berg C., Nassr R., Pang K. The further evolution of biotech. Nat Rev Drug Discov 2003, 2:75-79.
37. Delgado C., Francis G.E., Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992, 9:249-304.
38. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999, 17:780-783.
39. Goodson R.J., Katre N.V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (NY) 1990, 8:343-346.
40. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 2002, 54:487-504.
41. Atochina E.N., Balyasnikova I.V., Danilov S.M., Granger D.N., Fisher A.B., Muzykantov V.R. Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Am J Physiol 1998, 275:L806-L817.
42. Christofidou-Solomidou M., Scherpereel A., Wiewrodt R., et al. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol 2003, 285:L283-L292.
43. Wiewrodt R., Thomas A.P., Cipelletti L., et al. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood 2002, 99:912-922.
44. Antoniades C., Bakogiannis C., Tousoulis D., et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010, 122:S66-S73.
45. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 2011.
46. Maximov V.D., Reukov V.V., Barry J.N., Cochrane C., Vertegel A.A. Protein-nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia. Nanotechnology 2010, 21:265103.
47. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
48. Wang Y., Li Z., Han Y., Liang L.H., Ji A. Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab 2010, 11:182-196.
49. Li J.M., Zhang X., Nelson P.R., et al. Temporal evolution of gene expression in rat carotid artery following balloon angioplasty. J Cell Biochem 2007, 101:399-410.
50. Kroto H., Heath J.R., OBrien S.C., Curl R.F., Smalley R.E. C60: buckminster fullerene. Nature 1985, 318:162-163.
51. Bakry R., Vallant R.M., Najam-ul-Haq M., et al. Medicinal applications of fullerenes. Int J Nanomed 2007, 2:639-649.
52. Xiao L., Aoshima H., Saitoh Y., Miwa N. Highly hydroxylated fullerene localizes at the cytoskeleton and inhibits oxidative stress in adipocytes and a subcutaneous adipose-tissue equivalent. Free Radic Biol Med 2011.
53. Hsu H.C., Chiang Y.Y., Chen W.J., Lee Y.T. Water-soluble hexasulfobutyl 60 fullerene inhibits plasma lipid peroxidation by direct association with lipoproteins. J Cardiovasc Pharmacol 2000, 36:423-427.
54. Maeda R., Noiri E., Isobe H., et al. A water-soluble fullerene vesicle alleviates angiotensin II-induced oxidative stress in human umbilical venous endothelial cells. Hypertens Res 2008, 31:141-151.
55. Walker V.G., Li Z., Hulderman T., Schwegler-Berry D., Kashon M.L., Simeonova P.P. Potential in vitro effects of carbon nanotubes on human aortic endothelial cells. Toxicol Appl Pharmacol 2009, 236:319-328.
56. Niwa Y., Iwai N. Nanomaterials induce oxidized low-density lipoprotein cellular uptake in macrophages and platelet aggregation. Circ J 2007, 71:437-444.
57. Moller P., Mikkelsen L., Vesterdal L.K., et al. Hazard identification of particulate matter on vasomotor dysfunction and progression of atherosclerosis. Crit Rev Toxicol 2011, 41:339-368.
58. Simeonova P.P., Erdely A. Engineered nanoparticle respiratory exposure and potential risks for cardiovascular toxicity: predictive tests and biomarkers. Inhal Toxicol 2009, 21(Suppl. 1):68-73.
59. Wickline S.A., Neubauer A.M., Winter P.M., Caruthers S.D., Lanza G.M. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007, 25:667-680.
60. Demos S.M., Alkan-Onyuksel H., Kane B.J., et al. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J Am Coll Cardiol 1999, 33:867-875.
61. Kobayashi H., Kawamoto S., Jo S.K., Bryant H.L., Brechbiel M.W., Star R.A. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem 2003, 14:388-394.
62. Sato N., Kobayashi H., Hiraga A., et al. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn Reson Med 2001, 46:1169-1173.
63. Loo C., Lin A., Hirsch L., et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat 2004, 3:33-40.
64. Michalet X., Pinaud F.F., Bentolila L.A., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544.
65. McAteer M.A., von Zur Muhlen C., Anthony D.C., Sibson N.R., Choudhury R.P. Magnetic resonance imaging of brain inflammation using microparticles of iron oxide. Methods Mol Biol 2011, 680:103-115.
66. Schmitz S.A., Coupland S.E., Gust R., et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000, 35:460-471.
67. McCarthy J.R., Jaffer F.A., Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small 2006, 2:983-987.
68. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
69. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
70. Mangoni A.A., Jackson S.H. Homocysteine cardiovascular disease: current evidence future prospects. Am J Med 2002, 112:556-565.
71. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
72. Cui Y., Wei Q., Park H., Lieber C.M. Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science 2001, 293:1289-1292.
73. Wang J., Hong B., Kai J., et al. Mini sensing chip for point-of-care acute myocardial infarction diagnosis utilizing micro-electro-mechanical system and nano-technology. Adv Exp Med Biol 2009, 645:101-107.
74. Vogt S., Troitzsch D., Spath S., Moosdorf R. Efficacy of ion-selective probes in early epicardial in vivo detection of myocardial ischemia. Physiol Meas 2004, 25:N21-N26.
75. Sato M., Nakajima T., Goto M., Umezawa Y. Cell-based indicator to visualize picomolar dynamics of nitric oxide release from living cells. Anal Chem 2006, 78:8175-8182.
76. Hsiai T.K., Rouhanizadeh M., Tang T., Li C., Hwang J.L., Zhou C.W. Differentiation of oxidized low density lipoproteins by nanosensors. Sens Actuators B: Chem 2006, 114:788-798.
77. Magrez A., Kasas S., Salicio V., et al. Cellular toxicity of carbon-based nanomaterials. Nano Lett 2006, 6:1121-1125.
78. Stern S.T., McNeil S.E. Nanotechnology safety concerns revisited. Toxicol Sci 2008, 101:4-21.
79. Zolnik B.S., Gonzalez-Fernandez A., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.
80. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharmacol 2008, 5:487-495.
81. Bosi S., Feruglio L., Da Ros T., et al. Hemolytic effects of water-soluble fullerene derivatives. J Med Chem 2004, 47:6711-6715.
82. Domanski D.M., Klajnert B., Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 2004, 63:189-191.
83. Shah D.S., Sakthivel T., Toth I., Florence A.T., Wilderspin A.F. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J Pharm 2000, 208:41-48.
84. Radomski A., Jurasz P., Alonso-Escolano D., et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005, 146:882-893.
85. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437.
86. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 2007, 122:349-355.
87. Wang X., Ishida T., Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007, 119:236-244.
88. Chen B.X., Wilson S.R., Das M., Coughlin D.J., Erlanger B.F. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc Natl Acad Sci USA 1998, 95:10809-10813.
89. Al-Hanbali O., Rutt K.J., Sarker D.K., Hunter A.C., Moghimi S.M. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J Nanosci Nanotechnol 2006, 6:3126-3133.
90. Bertholon I., Vauthier C., Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res 2006, 23:1313-1323.
91. Vonarbourg A., Passirani C., Saulnier P., Simard P., Leroux J.C., Benoit J.P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A 2006, 78:620-628.